Health Catalyst, Inc. (NASDAQ:HCAT) Stock Holdings Lifted by Primecap Management Co. CA

Primecap Management Co. CA lifted its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 14.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,379,462 shares of the company’s stock after acquiring an additional 305,079 shares during the quarter. Primecap Management Co. CA owned 4.03% of Health Catalyst worth $15,205,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Principal Financial Group Inc. lifted its holdings in shares of Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after purchasing an additional 1,907 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Health Catalyst by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock worth $375,000 after acquiring an additional 2,831 shares during the period. ClariVest Asset Management LLC grew its stake in Health Catalyst by 1.2% during the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after acquiring an additional 3,302 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Health Catalyst by 9.1% in the second quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock worth $582,000 after purchasing an additional 7,589 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the transaction, the chief operating officer now owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $6.19, for a total transaction of $32,243.71. Following the transaction, the chief operating officer now directly owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,361 shares of company stock valued at $248,033. 2.70% of the stock is owned by insiders.

Health Catalyst Stock Performance

HCAT opened at $8.74 on Thursday. The firm has a market cap of $515.97 million, a P/E ratio of -4.72 and a beta of 1.31. The business has a 50 day moving average price of $7.20 and a 200 day moving average price of $6.90. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.04. The business had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. Health Catalyst’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.21) EPS. As a group, analysts anticipate that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HCAT shares. Stephens dropped their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Evercore ISI cut their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Piper Sandler cut their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Tuesday, August 20th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.42.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.